Current Headlines

  1. ProMetic Seeks Orphan Status For Lead IPF Drug
    10/20/2014

    Biopharmaceutical company ProMetic Life Sciences announced its intent to pursue idiopathic pulmonary fibrosis (IPF) as an orphan indication for its lead drug candidate PBI-4050.

  2. New Multiple Myeloma Drug To Enter Clinical Trials
    10/20/2014

    Researchers at the Imperial College London have developed a new type of drug for treating multiple myeloma which will enter clinical trials in late 2015.

  3. Alzheimer's Research Breakthrough Could Accelerate Development Of New Treatments
    10/20/2014

    Scientists at Massachusetts General Hospital (MGH) have developed an ‘Alzheimer's-in-a-dish’ breakthrough, which will allow them to replace the current poorly performing animal models with an innovative laboratory culture system for studying Alzheimer's disease and discovering new treatments.

  4. Sanofi Ally Shantha Begins Rotavirus Vaccine Phase 3 Trial
    10/17/2014

    Sanofi’s vaccine division, Sanofi Pasteur, reported that its affiliate Shantha Biotechnics has initiated the Phase 3 clinical trial in India for its investigational vaccine for rotavirus.

  5. Pfenex, PATH Link Arms For Vaccine Development Model
    10/17/2014

    Clinical stage biotech Pfenex announced that it has partnered with international nonprofit organization PATH in a multi-product research initiative to improve vaccine production.

  6. Auspherix, Domainex Join Forces Against Drug-Resistant Infections
    10/17/2014

    Early-stage anti-infectives firm Auspherix and U.K.-based drug discovery services firm Domainex announced a new collaboration to develop treatments that will combat antibiotic-resistant bacterial infections.

  7. Rich Pharmaceuticals Acquires Phorbol Esters For Hodgkin's Lymphoma
    10/17/2014

    Rich Pharmaceuticals has acquired the patents, intellectual property, and commercialization rights for phorbol esters in the treatment of Hodgkin's lymphoma.

  8. Nuvilex Files For Orphan Status For Cell-In-A-Box Therapy
    10/16/2014

    Clinical stage biotech firm Nuvilex announced that it has submitted an application seeking Orphan Drug Designation for its Cell-in-a-Box treatment for pancreatic cancer.

  9. GAPVAC Vaccine For Glioblastoma Advances To Clinical Trial
    10/16/2014

    immatics biotechnologies and its partner BioNTech AG reported that they are advancing the Glioma Actively Personalized VAccine Consortium (GAPVAC) into a Phase 1/2 clinical trial to investigate the concept of fully personalized therapeutic vaccines against cancer.

  10. FDA Accepts Pfizer’s NDA For Breast Cancer Drug
    10/16/2014

    Pfizer announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for its breast cancer drug palbociclib. The company is seeking approval for palbociclib in combination with letrozole as a first-line treatment for patients with advanced breast cancer.

Newsletter Signup
Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.